Compare D Wave Quantum Inc (QBTS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs Recursion Pharmaceuticals Inc — how do they compare? D Wave Quantum Inc trades at $14.79 (market cap $5.54B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: D Wave Quantum Inc is far larger — about 2.6× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold D Wave Quantum Inc for 32 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| QBTS | RXRX | |
|---|---|---|
Market Cap | $5.54B | $2.14B |
Volume | 16,671,452 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $44.78 | $6.79 |
52-Week Low | $12.98 | $2.84 |
Typical Hold Time | 32 Days | 22 Days |
Enterprise Value | $5.04B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D-Wave Quantum Inc. (QBTS) trades at $15.22, down 3.61% on the day, reflecting a bearish technical trend. The company shows significant financial strain with a net income margin of -2001.59% and negative cash flow from operations. Despite this, all 13 covering analysts maintain a Buy rating with a consensus price target of $34.38, highlighting a stark divergence between current performance and long-term optimism.
The outlook is highly speculative. The potential reward is substantial if D-Wave achieves commercial success in quantum computing, but the risk is extreme due to persistent losses, high cash burn, and multiple ongoing securities fraud investigations, making it suitable only for risk-tolerant investors.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
